Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
PBYI Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 21, 2026
Report Source: 2026 1st Quarter Report
Puma Biotechnology Inc. Stock Analysis PBYI
United States Health Care Small Cap Report: Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.
Read More Puma Biotechnology Inc (PBYI) Chart
Key Statistics of Puma Biotechnology Inc (PBYI)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$7.64Volume
440.37KP/E Ratio (TTM)
12.9752 Week Range
Market Cap
358.84MAvg. Volume
228.96KDividend Yield
-Financial Metrics & Statements of Puma Biotechnology Inc (PBYI)
FAQ's for Puma Biotechnology Inc (PBYI)
- According to Musaffa’s Shariah screening methodology, Puma Biotechnology Inc (PBYI) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Puma Biotechnology Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Puma Biotechnology Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Puma Biotechnology Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Puma Biotechnology Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Puma Biotechnology Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.